Read by QxMD icon Read

Uri ladabaum

Omar Metwally, Seth Blumberg, Uri Ladabaum, Sidhartha R Sinha
BACKGROUND: Although cancer screening reduces morbidity and mortality, millions of people worldwide remain unscreened. Social media provide a unique platform to understand public sentiment toward tools that are commonly used for cancer screening. OBJECTIVE: The objective of our study was to examine public sentiment toward colonoscopy, mammography, and Pap smear and how this sentiment spreads by analyzing discourse on Twitter. METHODS: In this observational study, we classified 32,847 tweets (online postings on Twitter) related to colonoscopy, mammography, or Pap smears using a naive Bayes algorithm as containing positive, negative, or neutral sentiment...
June 7, 2017: Journal of Medical Internet Research
David A Johnson, David Lieberman, John M Inadomi, Uri Ladabaum, Richard C Becker, Seth A Gross, Kristin L Hood, Susan Kushins, Mark Pochapin, Douglas J Robertson
BACKGROUND & AIMS: The incidence and predictors of non-gastrointestinal (GI) adverse events (AEs) after colonoscopy are not well-understood. We studied the effects of antithrombotic agents, cardiopulmonary comorbidities, and age on risk of non-GI AEs after colonoscopy. METHODS: We performed a retrospective longitudinal analysis to assess the diagnosis, procedure, and prescription drug codes in a United States commercial claims database (March 2010-March 2012). Data from patients at increased risk (n = 82,025; defined as patients with pulmonary comorbidities or cardiovascular disease requiring antithrombotic medications) were compared with data from 398,663 average-risk patients...
December 23, 2016: Clinical Gastroenterology and Hepatology
Sheila Kumar, Nirav Thosani, Uri Ladabaum, Shai Friedland, Ann M Chen, Rajan Kochar, Subhas Banerjee
BACKGROUND AND AIMS: The 6-minute withdrawal time for colonoscopy, widely considered the standard of care, is controversial. The skill and technique of endoscopists may be as important as, or more important than, withdrawal time for adenoma detection. It is unclear whether a shorter withdrawal time with good technique yields an acceptable lesion detection rate. Our objective was to evaluate a 3-minute versus a 6-minute withdrawal time by using segmental tandem colonoscopy. METHODS: We performed a prospective, randomized trial by using 4 expert endoscopists...
June 2017: Gastrointestinal Endoscopy
David Lieberman, Uri Ladabaum, Marcia Cruz-Correa, Carla Ginsburg, John M Inadomi, Lawrence S Kim, Francis M Giardiello, Richard C Wender
Importance: Colorectal cancer (CRC) is the second-leading cause of cancer death in the United States. Screening can reduce CRC mortality and incidence, and numerous screening options, although available, complicate informed decision making. This review provides evidence-based tools for primary care physicians to identify patients with higher-than-average-risk and engage patients in informed decision making about CRC screening options. Observations: Recently, the US Preventive Services Task Force recommended any of 8 CRC screening approaches for average-risk individuals, beginning at age 50 years...
November 22, 2016: JAMA: the Journal of the American Medical Association
Frank W Chen, Vandana Sundaram, Thomas A Chew, Uri Ladabaum
BACKGROUND & AIMS: The incidence of colorectal cancer (CRC) is increasing in the United States among adults younger than the age of 50 years. Studies of young-onset CRC have focused on outcomes and treatment patterns. We examined patient presentation, provider evaluation, and time to diagnosis, which can affect stage and prognosis. METHODS: In a retrospective study, we collected data from patients with a diagnosis of colorectal adenocarcinoma, confirmed by pathologists, seen at the Stanford Cancer Institute from January 1, 2008, through December 31, 2014...
May 2017: Clinical Gastroenterology and Hepatology
Uri Ladabaum, Ajitha Mannalithara
BACKGROUND & AIMS: We developed a model to determine whether a multitarget stool DNA (MT-sDNA) test that detects colorectal cancer (CRC) and polyps with higher sensitivity and lower specificity, but at a higher cost, than the fecal immunochemical test (FIT) can be used in screening. METHODS: We used a Markov model of average-risk CRC screening to compare the effectiveness and cost effectiveness of screening with the MT-sDNA test vs FIT or colonoscopy. We accounted for the complex longitudinal participation patterns observed in organized programs vs opportunistic screening, as well as organized programs' patient support costs and differential payment rates by commercial insurers vs Medicare...
September 2016: Gastroenterology
Jan T Lowery, Dennis J Ahnen, Paul C Schroy, Heather Hampel, Nancy Baxter, C Richard Boland, Randall W Burt, Lynn Butterly, Megan Doerr, Mary Doroshenk, W Gregory Feero, Nora Henrikson, Uri Ladabaum, David Lieberman, Elizabeth G McFarland, Susan K Peterson, Martha Raymond, N Jewel Samadder, Sapna Syngal, Thomas K Weber, Ann G Zauber, Robert Smith
Persons with a family history (FH) of colorectal cancer (CRC) or adenomas that are not due to known hereditary syndromes have an increased risk for CRC. An understanding of these risks, screening recommendations, and screening behaviors can inform strategies for reducing the CRC burden in these families. A comprehensive review of the literature published within the past 10 years has been performed to assess what is known about cancer risk, screening guidelines, adherence and barriers to screening, and effective interventions in persons with an FH of CRC and to identify FH tools used to identify these individuals and inform care...
September 1, 2016: Cancer
Uri Ladabaum, Ashley Patel, Ajitha Mannalithara, Vandana Sundaram, Aya Mitani, Manisha Desai
BACKGROUND: Tailoring screening to colorectal cancer (CRC) risk could improve screening effectiveness. Most CRCs arise from advanced neoplasia (AN) that dwells for years. To date, no available colorectal neoplasia risk score has been validated externally in a diverse population. The authors explored whether the National Cancer Institute (NCI) CRC risk-assessment tool, which was developed to predict future CRC risk, could predict current AN prevalence in a diverse population, thereby allowing its use in risk stratification for screening...
September 1, 2016: Cancer
Dan Li, Marita C Bautista, Sheng-Fang Jiang, Paras Daryani, Marilyn Brackett, Mary Anne Armstrong, Yun-Yi Hung, Debbie Postlethwaite, Uri Ladabaum
OBJECTIVES: Gastric intestinal metaplasia and dysplasia are precursor lesions for adenocarcinoma. The risks of progression to malignancy from these lesions are not well characterized, particularly in the US populations. METHODS: We identified 4,331 Kaiser Permanente Northern California members who were diagnosed with gastric intestinal metaplasia or dysplasia between 1997 and 2006 and followed them through December 2013. The incident rates of gastric adenocarcinoma, relative risks in comparison with the Kaiser Permanente general population, and predictors of progression to malignancy were investigated...
August 2016: American Journal of Gastroenterology
Naresh T Gunaratnam, Mehmet Akce, Riad Al Natour, Angela N Bartley, Ann F Fioritto, Kristen Hanson, Uri Ladabaum
No abstract text is available yet for this article.
May 2016: American Journal of Gastroenterology
Jasmine Zia, Jessica Schroeder, Sean Munson, James Fogarty, Linda Nguyen, Pamela Barney, Margaret Heitkemper, Uri Ladabaum
OBJECTIVES: Seventy percent of patients with irritable bowel syndrome (IBS) identify certain foods as triggers for their symptom flare-ups. To help identify potential trigger foods, practitioners often rely on patient food and gastrointestinal (GI) symptom journaling. The aim of the study was to evaluate the feasibility and usability of a novel food and symptom journal app, specifically designed for patients with IBS. Secondary aims were to explore the effect of using the app on GI symptoms and to describe associations between diet and GI symptoms suggested by individual patient data...
2016: Clinical and Translational Gastroenterology
Uri Ladabaum, Robert E Schoen
No abstract text is available yet for this article.
April 2016: Gastroenterology
Samir Gupta, Elizabeth T Jacobs, John A Baron, David A Lieberman, Gwen Murphy, Uri Ladabaum, Amanda J Cross, Rodrigo Jover, Lin Liu, Maria Elena Martinez
OBJECTIVE: For individuals with 1-2 small (<1 cm) low-risk colorectal adenomas, international guidelines range from no surveillance to offering surveillance colonoscopy in 5-10 years. We hypothesised that the risks for metachronous advanced neoplasia (AN) among patients with low-risk adenomas differ based on clinical factors distinct from those currently used. DESIGN: We pooled data from seven prospective studies to assess the risk of metachronous AN. Two groups with 1-2 small adenomas were defined based on guidelines from the UK (n=4516) or the European Union (EU)/US (n=2477)...
March 2017: Gut
Andrew T Chan, Uri Ladabaum
No abstract text is available yet for this article.
January 2016: Gastroenterology
Uri Ladabaum, James M Ford, Myriam Martel, Alan N Barkun
No abstract text is available yet for this article.
September 2015: Gastroenterology
Uri Ladabaum, Lourdes Alvarez-Osorio, Thomas Rösch, Bernd Brueggenjuergen
BACKGROUND AND STUDY AIMS: Colorectal cancer (CRC) screening strategies in Germany include guaiac-based fecal occult blood testing (gFOBT) starting at age 50 and a switch to colonoscopy at age 55 or continued gFOBT testing, but screening utilization is limited. Blood-based biomarkers, such as methylated Septin 9 DNA ( (m) SEPT9), may improve screening rates. We performed a cost-effectiveness analysis of current and emerging CRC screening strategies in Germany. METHODS: Using a validated Markov model, we compared annual gFOBT for ages 50 through 54 followed by biennial testing until age 75 (FOBT) or by colonoscopy at ages 55 and 65 (FOBT/COLO 55,65), substitution of fecal immunochemical testing (FIT) for gFOBT (FIT, FIT/COLO 55,65), and annual or biennial plasma (m) SEPT9 testing...
June 2014: Endoscopy International Open
Michael P Douglas, Uri Ladabaum, Mark J Pletcher, Deborah A Marshall, Kathryn A Phillips
The American College of Medical Genetics and Genomics (ACMG) recommends that mutations in 56 genes for 24 conditions are clinically actionable and should be reported as secondary findings after whole-genome sequencing (WGS). Our aim was to identify published economic evaluations of detecting mutations in these genes among the general population or among targeted/high-risk populations and conditions and identify gaps in knowledge. A targeted PubMed search from 1994 through November 2014 was performed, and we included original, English-language articles reporting cost-effectiveness or a cost-to-utility ratio or net benefits/benefit-cost focused on screening (not treatment) for conditions and genes listed by the ACMG...
February 2016: Genetics in Medicine: Official Journal of the American College of Medical Genetics
Kathryn A Phillips, Mark J Pletcher, Uri Ladabaum
No abstract text is available yet for this article.
2015: Technology and Health Care: Official Journal of the European Society for Engineering and Medicine
Sara J Knight, Ateesha F Mohamed, Deborah A Marshall, Uri Ladabaum, Kathryn A Phillips, Judith M E Walsh
BACKGROUND: . While choices about genetic testing are increasingly common for patients and families, and public opinion surveys suggest public interest in genomics, it is not known how adults from the general population value genetic testing for heritable conditions. We sought to understand in a US sample the relative value of the characteristics of genetic tests to identify risk of hereditary colorectal cancer, among the first genomic applications with evidence to support its translation to clinical settings...
January 14, 2015: Medical Decision Making: An International Journal of the Society for Medical Decision Making
Uri Ladabaum, Ajitha Mannalithara, Lina Jandorf, Steven H Itzkowitz
BACKGROUND: Colorectal cancer (CRC) screening is underused by minority populations, and patient navigation increases adherence with screening colonoscopy. In this study, the authors estimated the cost-effectiveness of navigation for screening colonoscopy from the perspective of a payer seeking to improve population health. METHODS: A validated model of CRC screening was informed with inputs from navigation studies in New York City (population: 43% African American, 49% Hispanic, 4% white, 4% other; base-case screening: 40% without navigation, 65% with navigation; navigation costs: $29 per colonoscopy completer, $21 per noncompleter, $3 per non-navigated individual)...
April 1, 2015: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"